PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition
Summary
This expert trend report explores in-licensing trends among FDA New Molecule Entity (NME) approvals 2014-2018, and analyzes how licensing patterns affect propensity to outsource finished dose manufacture. This report is critical for establishing an understanding of the ways bio/pharmaceutical companies source their drugs, and the factor that make them more likely to engage a contract manufacturing organization (CMO).
Scope
Reasons to Buy
Summary
This expert trend report explores in-licensing trends among FDA New Molecule Entity (NME) approvals 2014-2018, and analyzes how licensing patterns affect propensity to outsource finished dose manufacture. This report is critical for establishing an understanding of the ways bio/pharmaceutical companies source their drugs, and the factor that make them more likely to engage a contract manufacturing organization (CMO).
Scope
- CMO executives who must have a deep understanding of the NME approvals landscape to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Pharmaceutical and biotech companies evaluating potential licensing deals as a licensor or licensee.
- Investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
- Overview of novel drugs (NMEs) approved by FDA 2014-2018
- Detailed analysis of dose outsourcing likelihood by: licensing status, market cap, molecule type
- Spotlight on licensing deals and outsourcing propensity
- Detailed methodology explains use of data from the The publisher Pharma Intelligence Center databases
Table of Contents
1 Table of Contents2 List of Tables
3 List of Figures
4 Executive Summary
5 Introduction
6 Licensing of New Molecular Entities Approved 2014-2018
7 Timing of Licensing Deals
7.1 Chronology of Licensing and Outsourcing
8 Outsourcing Propensity by Source of NME
8.1 Product Source and Outsourcing Propensity by Market Cap
9 Trends by Molecule Type
9.1 In-Licensing by Molecule Type
9.1.1 Spotlight On: Cell and Gene Therapies
9.2 Dose Manufacture by Molecule Type
10 Company Analysis
11 What It Means
12 Notes on Methodology
13 Appendix
13.1 Bibliography
13.2 Primary Research - Key Opinion Leaders Featured in This Report
13.3 About the Authors
13.4 Contact Information
13.5 Disclaimer
List of Tables
Table 1: Breakdown of Approvals 2014-2018 by Company Market Cap Band
List of Figures
Figure 1: Source of NMEs Approved 2014-2018
Figure 2: Source of NMEs Approved 2014-2018, by Year
Figure 3: Status of Approved In-Licensed NMEs at Time of Licensing Deal, 2014-2018
Figure 4: Status of Approved In-Licensed NMEs at Time of Licensing Deal, 2014-2018, by Year
Figure 5: Chronology of Licensing and Outsourcing for NMEs Approved 2014-2018
Figure 6: Source of Dose-Outsourced NMEs (Approved 2014-2018)
Figure 7: Dose Form Manufacture by Source of NMEs Approved 2014-2018
Figure 8: Dose Outsourcing of NMEs (Approved 2014-2018) by Company Market Cap and NME Source
Figure 9: NME Source by Molecule Type
Figure 10: Dose Manufacture of In-licensed NMEs Approved 2014-2018, by Molecule Type
Figure 11: Top 9 Companies by NME Approvals 2014-2018, by NME Source
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc
- Astellas Pharma
- AstraZeneca Plc
- Bristol-Myers Squibb
- Cabaret Biotech
- ClearView Healthcare Partners
- CSL
- Cytovant Sciences
- Eli Lilly and Co
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Legend Biotech
